Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/894
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Murphy, Declan | - |
dc.contributor.author | Lawrentschuk, Nathan | - |
dc.contributor.other | Sathianathen, Niranjan | - |
dc.contributor.other | Van den Bergh, Roderick | - |
dc.date | 2015-10 | - |
dc.date.accessioned | 2016-11-22T00:25:42Z | - |
dc.date.available | 2016-11-22T00:25:42Z | - |
dc.date.issued | 2015-09 | - |
dc.identifier.citation | 2016 Jun;117(6):856-7 | en_US |
dc.identifier.issn | 1464-410X | en_US |
dc.identifier.uri | http://hdl.handle.net/11434/894 | - |
dc.description.abstract | To reduce overtreatment of indolent prostate cancer (PCa), urologists have embraced active surveillance (AS) as a management strategy for low-risk PCa; however, patterns-of-care studies are now showing that AS is also being used for patients with intermediate-risk disease. A contemporary Australian study of 980 men reported that 8.9% of men with intermediate-risk disease were placed on AS, of whom 53.8% had Gleason score (GS) 3+4 PCa and 10.4% had GS 4+3 PCa [1]. The most recent update from the CaPSURE database also reflected this trend in AS, but questions remain about the safety of this practice, particularly as the majority of AS protocols worldwide exclude men with GS 4 PCa, unless their life expectancy is limited. | en_US |
dc.publisher | Wiley | en_US |
dc.subject | Gleason Pattern 4 | en_US |
dc.subject | Gleason Score | en_US |
dc.subject | Biopsy | en_US |
dc.subject | Prostate Cancer | en_US |
dc.subject | Active Surveillance | en_US |
dc.subject | UroRenal | en_US |
dc.subject | Prostatectomy | en_US |
dc.subject | Prognosis | en_US |
dc.subject | CaPSURE Database | en_US |
dc.subject | Epworth Prostate Centre, Epworth Healthcare, Victoria, Australia | en_US |
dc.subject | UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia | en_US |
dc.title | Gleason pattern 4: active surveillance no more. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.doi | 10.1111/bju.13333 | en_US |
dc.identifier.journaltitle | BJU International | en_US |
dc.description.pubmeduri | https://www.ncbi.nlm.nih.gov/pubmed/26390094 | en_US |
dc.description.affiliates | Division of Cancer Surgery, University of Melbourne, Victoria, Australia | en_US |
dc.description.affiliates | Department of Urology, Royal Melbourne Hospital, Victoria, Australia. | en_US |
dc.description.affiliates | Faculty of Medicine, Monash University, Melbourne, Victoria, Australia. | en_US |
dc.description.affiliates | Departments of Urology and Surgery, Royal Melbourne Hospital, Melbourne, Vic., Australia. | en_US |
dc.description.affiliates | Department of Surgery, The Austin Hospital, Heidelberg, Victoria., Australia. | en_US |
dc.description.affiliates | Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia. | en_US |
dc.type.studyortrial | Cohort Study | en_US |
dc.type.contenttype | Text | en_US |
Appears in Collections: | Cancer Services Epworth Prostate Centre UroRenal, Vascular |
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.